A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover

被引：0
|
作者：
Cupissol, Didier
Seiwert, Tanguy Y.
Fayette, Jerome
Ehrnrooth, Eva
Blackman, Alice Sarah
Cong, Xiuyu Julie
Cohen, Ezra E. W.
机构：
[1] Ctr Val dAurelle, Montpellier, France
[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Boehringer Ingelheim GmbH & Co KG, Copenhagen, Denmark
[5] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6001
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
    Ho, A. L.
    Adkins, D. R.
    Hanna, G. J.
    Bruce, J.
    Ahn, M. J.
    Docampo, L. Iglesias
    Kang, H.
    Wong, D. J.
    Psyrri, A.
    Gillison, M.
    Brana, I.
    Liu, Y. C.
    Hsieh, C. Y.
    Hong, M. H.
    Zhang, Z.
    Balsara, B.
    Saunders, A.
    Hernandez, A. Gasco
    Dale, S.
    Haddad, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S1286 - S1287
  • [42] Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.
    Ji, Dongmei
    Sang, Youzhou
    Liu, Xin
    Guo, Yanjing
    Yang, Yanan
    Chen, Guangliang
    Dong, Shu
    Wang, Yulong
    He, Xiayun
    Ying, Hongmei
    Lu, Xueguan
    Wang, Yu
    Hu, Chaosu
    Ji, Qinghai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.
    Kao, Hsiang-fong
    Liao, Bin-Chi
    Huang, Yen-Lin
    Huang, Huai-Cheng
    Chen, Chun-Nan
    Chen, Tseng-Cheng
    Hong, Yuan-Jing
    Chan, Ching-Yi
    Hong, Ruey-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study
    Zandberg, D. P.
    Algazi, A.
    Jimeno, A.
    Good, J.
    Fayette, J.
    Bouganim, N.
    Ready, N.
    Clement, P.
    Goswami, T.
    Jarkowski, A.
    Armstrong, J.
    Asubonteng, K.
    Melillo, G.
    Mesia, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 13 - 13
  • [45] Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study
    Zandberg, D.
    Algazi, A.
    Jimeno, A.
    Good, J. S.
    Fayette, J.
    Bouganim, N.
    Ready, N.
    Clement, P. M.
    Goswmi, T.
    Jarkowski, A.
    Armstrong, J. M.
    Asubonteng, K.
    Melillo, G.
    Mesia, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Nutritional status (NS) as a strong predictor for immunotherapy (IT) outcome in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo Castaneda, D. H.
    Vieito, M.
    Santa Gadea, O. Saavedra
    Gardeazabal, I.
    Villacampa Javierre, G.
    Aguilar, S.
    Martin Liberal, J.
    Bescos, C.
    Lorente, J.
    Giralt, J.
    Benavente, S.
    Fuentes, J. F.
    Temprana-Salvador, J.
    Alberola, M.
    Dienstmann, R.
    Garralda, E.
    Felip, E.
    Brana, I.
    ANNALS OF ONCOLOGY, 2020, 31 : S671 - S672
  • [47] Interim analysis of the combination of durvalumab and cetuximab in a phase II trial of patients with recurrent and metastatic head and neck squamous cell carcinoma
    Gulati, Shuchi
    Palackdharry, Sarah
    Weatherford, Layne
    Wilson, Sarah
    Desai, Shireen
    Steele, Aubrey
    Riaz, Kashif
    Takiar, Vinita
    Draper, Trisha
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [48] Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1)
    Cohen, E.
    Licitra, L.
    Burtness, B.
    Fayette, J.
    Gauler, T.
    Clement, P. M.
    Grau, J. J.
    del Campo, J. M.
    Mailliez, A.
    Haddad, R. I.
    Vermorken, J. B.
    Tahara, M.
    Guigay, J.
    Geoffrois, L.
    Merlano, M. C.
    Cong, X. J.
    Gibson, N.
    Solca, F.
    Ehrnrooth, E.
    Machiels, J. P. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 868 - 869
  • [49] Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
    Ferris, R. L.
    Haddad, R.
    Even, C.
    Tahara, M.
    Dvorkin, M.
    Ciuleanu, T. E.
    Clement, P. M.
    Mesia, R.
    Kutukova, S.
    Zholudeva, L.
    Daste, A.
    Caballero-Daroqui, J.
    Keam, B.
    Vynnychenko, I.
    Lafond, C.
    Shetty, J.
    Mann, H.
    Fan, J.
    Wildsmith, S.
    Morsli, N.
    Fayette, J.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2020, 31 (07) : 942 - 950
  • [50] A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
    Fury, Matthew G.
    Sherman, Eric
    Lisa, Donna
    Agarwal, Neeraj
    Algazy, Kenneth
    Brockstein, Bruce
    Langer, Corey
    Lim, Dean
    Mehra, Ranee
    Rajan, Sandeep K.
    Korte, Susan
    Lipson, Brynna
    Yunus, Furhan
    Tanvetyanon, Tawee
    Smith-Marrone, Stephanie
    Ng, Kenneth
    Xiao, Han
    Hague, Sofia
    Pfister, David G.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (11): : 1391 - 1398
12345